Academia

What We're Reading: Drug Pricing Debate; Judge Rules Against Walgreens; Predicting TBI Outcomes

August 11th 2022, 2:02pm

Policy observers and industry stakeholders debate the possible spillover effects of Medicare drug pricing reform in the employer-based insurance market; a California federal judge rules Walgreens could be held liable for not investigating suspicious orders of opioids in San Francisco; a blood test performed the day of a traumatic brain injury (TBI) can predict which patients may die and who may survive with a disability.

Topline KarMMa-3 Results for Ide-Cel in Multiple Myleoma Show “Significant Improvement” in PFS

August 10th 2022, 3:35pm

Ide-cel is a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, which uses the process of genetically modifying a patient’s T cells and infusing them back into the patient to attack the cancer.

Dr Paolo Caimi Highlights the Need for Access and Better Treatments in DLBCL

August 8th 2022, 9:40pm

Facilitating access to treatments for diffuse large B-cell lymphoma (DLBCL) remains a top issue.

Early Use of Novel Therapies in Multiple Myeloma Could Target Bone Marrow Microenvironment

July 28th 2022, 4:29pm

Authors explained how multiple myeloma emerges from earlier clinical phases and the tumor’s microenvironment in the early course of the disease plays a critical role in the survival of myeloma cells.

With Successor to R-CHOP on Horizon, Habermann Says DLBCL Treatment Choices Create “Complicated World”

July 17th 2022, 4:08pm

Survey Finds Shift in Clinician Views of MRD Status in Treatment Decisions for Multiple Myeloma

July 16th 2022, 1:10pm

Results looking at acceptance of minimal residual disease (MRD) status found that 60% of participants “would change at least one decision based on an MRD result,” and 54% would use both MRD status and disease risk to make decisions.

New Genetic Eye Disease Found by NIH Researchers

June 14th 2022, 4:48pm

National Institutes of Health (NIH) researchers found a new form of macular dystrophy, which is a cause of central vision loss.

Over 6 Years, First-line Brentuximab Vedotin Cuts Risk of Death in Hodgkin Lymphoma by 41%

June 4th 2022, 4:17am

Data presented at ASCO show that after 6 years, patients with advanced Hodgkin lymphoma who were treated with a combination of brentuximab vedotin and chemotherapy had a sharply reduced risk of death and a reduced risk of a secondary cancer.

SHINE: Adding Ibrutinib to Treatment Improves PFS by 50% for Older Patients With Mantle Cell Lymphoma

June 3rd 2022, 12:00pm

Findings from the phase 3 SHINE trial could make ibrutinib the standard treatment option for older patients with mantle cell lymphoma (MCL), who often cannot tolerate chemotherapy or transplant strategies, according to study authors.

Review Finds Cannabis Treatment for Sleep Disorders Warrants Further Investigation

June 1st 2022, 4:26pm

Encouraging outcomes in recent studies have the authors of a recent review calling for more research on the effect of cannabinoids on sleep disorders.